|Articles|August 27, 2018

Going Against the Norm: Testing A New Skin Disinfectant

Can we find an alternative for chlorhexidine gluconate?

Decolonizing a patient’s skin is critical for reducing microbial burden during hospitalization, especially before surgery to reduce the risk of surgical site infections, as well as other health care-associated infections (HAIs). Topical antiseptics are commonly used to clean and decolonize patients who may be going into surgery or those who are unable to clean themselves and who are at risk for infection (ie, patients in intensive care units). The use of these antiseptics come with added caveats, though, and so, there is a continued push for finding new methods for decolonizing patients’ skin.

The gold standard topical antiseptic is chlorhexidine gluconate because it can quickly and effectively rid the skin of microbes; however, there is also a risk for skin irritation and allergies when using the antiseptic, which can result in skin breakdown and pain for the patient. Moreover, chlorhexidine gluconate should not be used on patients with compromised skin. With concern for microbial resistance continuing to grow, scientists are searching for new agents that can be used for disinfection and decolonization on all groups of patients.

As such, the authors of a new research study tested a multi-ingredient surfactant colloidal silver technology to see if it was noninferior to a 4% chlorhexidine gluconate antiseptic.

The team of investigators recruited 81 participants in Bozeman, Montana, who were in good health and who, for 14 days before the test portion of the study, avoided medicated soaps, lotions, deodorants, shampoos, and skin contact with solvents, detergents, etc. Seventy-two hours before the experiment, the investigators screened a skin sample via a sterile cylinder in which the 3.46 cm inside the cylinder was the test area. On each participant, they marked 4 areas of the inguinal region, of which 3 were then sampled (1 as a baseline, 1 at 10 minutes, and 1 at 6 hours). These sites were sampled for microbial loads after 6 hours were covered with sterile gauze and bandages and then sampled. The investigators then plated the samples and microbial colonies were manually counted and data was then assessed.

A total of 40 participants received colloidal silver and 41 received 4% chlorhexidine gluconate as treatments.

For the 10-minute group, the investigators found the mean recovery of microbial flora to be 3.83 for colloidal silver and 3.64 for 4% chlorhexidine gluconate, while the 6-hour group had a recovery average of 3.49 for colloidal silver and 3.34 for 4% chlorhexidine gluconate. The average treatment efficacy was .18-.21, meaning that the colloidal silver was noninferior to the 4% chlorhexidine gluconate. The investigators note that “the 95% confidence interval of the test product to the control product with a margin of 0.65 was established as the upper limit of noninferiority.”

Ultimately, the treatments were of similar efficacy and although the sample size was small, the results should prove encouraging for future efforts to find nonchlorhexidine gluconate antiseptics for skin decolonization.

Furthermore, the research is timely given the latest US Food and Drug Administration guidance that warned of a greater chance for safety concerns related to chlorhexidine gluconate-containing products. Since chlorhexidine gluconate is widely used, alternatives should be investigated for future application and hopefully, they will prove less abrasive to the skin, but still efficacious against hardy microbes.


Related to this article

Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.